vs
Krystal Biotech, Inc.（KRYS）与NEUROCRINE BIOSCIENCES INC（NBIX）财务数据对比。点击上方公司名可切换其他公司
NEUROCRINE BIOSCIENCES INC的季度营收约是Krystal Biotech, Inc.的7.5倍（$805.5M vs $107.1M）。Krystal Biotech, Inc.净利率更高（48.0% vs 19.1%，领先28.9%）。NEUROCRINE BIOSCIENCES INC同比增速更快（28.3% vs 17.5%）。NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $75.4M）。过去两年Krystal Biotech, Inc.的营收复合增速更高（53.8% vs 25.0%）
Krystal Biotech是一家处于临床阶段的生物技术企业，专注于研发和商业化针对罕见重症皮肤病的新型基因疗法，主要面向北美和欧洲市场，服务缺乏有效常规治疗方案的单基因皮肤病患者。
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
KRYS vs NBIX — 直观对比
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $107.1M | $805.5M |
| 净利润 | $51.4M | $153.7M |
| 毛利率 | — | 97.8% |
| 营业利润率 | 41.5% | 26.2% |
| 净利率 | 48.0% | 19.1% |
| 营收同比 | 17.5% | 28.3% |
| 净利润同比 | 13.0% | 49.1% |
| 每股收益（稀释后） | $1.69 | $1.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $107.1M | $805.5M | ||
| Q3 25 | $97.8M | $794.9M | ||
| Q2 25 | $96.0M | $687.5M | ||
| Q1 25 | $88.2M | $572.6M | ||
| Q4 24 | $91.1M | $627.7M | ||
| Q3 24 | $83.8M | $622.1M | ||
| Q2 24 | $70.3M | $590.2M | ||
| Q1 24 | $45.3M | $515.3M |
| Q4 25 | $51.4M | $153.7M | ||
| Q3 25 | $79.4M | $209.5M | ||
| Q2 25 | $38.3M | $107.5M | ||
| Q1 25 | $35.7M | $7.9M | ||
| Q4 24 | $45.5M | $103.1M | ||
| Q3 24 | $27.2M | $129.8M | ||
| Q2 24 | $15.6M | $65.0M | ||
| Q1 24 | $932.0K | $43.4M |
| Q4 25 | — | 97.8% | ||
| Q3 25 | — | 98.2% | ||
| Q2 25 | — | 98.4% | ||
| Q1 25 | — | 98.4% | ||
| Q4 24 | — | 98.5% | ||
| Q3 24 | — | 98.7% | ||
| Q2 24 | — | 98.4% | ||
| Q1 24 | — | 98.5% |
| Q4 25 | 41.5% | 26.2% | ||
| Q3 25 | 42.3% | 30.1% | ||
| Q2 25 | 40.9% | 21.2% | ||
| Q1 25 | 41.0% | 4.1% | ||
| Q4 24 | 45.4% | 22.6% | ||
| Q3 24 | 26.8% | 29.5% | ||
| Q2 24 | 12.2% | 24.6% | ||
| Q1 24 | -14.8% | 19.3% |
| Q4 25 | 48.0% | 19.1% | ||
| Q3 25 | 81.2% | 26.4% | ||
| Q2 25 | 39.9% | 15.6% | ||
| Q1 25 | 40.5% | 1.4% | ||
| Q4 24 | 49.9% | 16.4% | ||
| Q3 24 | 32.4% | 20.9% | ||
| Q2 24 | 22.2% | 11.0% | ||
| Q1 24 | 2.1% | 8.4% |
| Q4 25 | $1.69 | $1.49 | ||
| Q3 25 | $2.66 | $2.04 | ||
| Q2 25 | $1.29 | $1.06 | ||
| Q1 25 | $1.20 | $0.08 | ||
| Q4 24 | $1.53 | $1.00 | ||
| Q3 24 | $0.91 | $1.24 | ||
| Q2 24 | $0.53 | $0.63 | ||
| Q1 24 | $0.03 | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $496.3M | $713.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $3.3B |
| 总资产 | $1.3B | $4.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $496.3M | $713.0M | ||
| Q3 25 | $392.6M | $340.2M | ||
| Q2 25 | $353.8M | $264.0M | ||
| Q1 25 | $308.8M | $194.1M | ||
| Q4 24 | $344.9M | $233.0M | ||
| Q3 24 | $374.0M | $349.1M | ||
| Q2 24 | $345.8M | $139.7M | ||
| Q1 24 | $359.0M | $396.3M |
| Q4 25 | $1.2B | $3.3B | ||
| Q3 25 | $1.1B | $3.0B | ||
| Q2 25 | $1.0B | $2.7B | ||
| Q1 25 | $984.7M | $2.5B | ||
| Q4 24 | $946.4M | $2.6B | ||
| Q3 24 | $885.8M | $2.7B | ||
| Q2 24 | $838.9M | $2.5B | ||
| Q1 24 | $799.2M | $2.4B |
| Q4 25 | $1.3B | $4.6B | ||
| Q3 25 | $1.2B | $4.3B | ||
| Q2 25 | $1.1B | $3.9B | ||
| Q1 25 | $1.1B | $3.7B | ||
| Q4 24 | $1.1B | $3.7B | ||
| Q3 24 | $982.3M | $3.5B | ||
| Q2 24 | $917.7M | $3.3B | ||
| Q1 24 | $853.3M | $3.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.5M | $388.4M |
| 自由现金流经营现金流 - 资本支出 | $75.4M | $386.0M |
| 自由现金流率自由现金流/营收 | 70.4% | 47.9% |
| 资本支出强度资本支出/营收 | 2.0% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.51× | 2.53× |
| 过去12个月自由现金流最近4个季度 | $188.9M | $743.9M |
8季度趋势，按日历期对齐
| Q4 25 | $77.5M | $388.4M | ||
| Q3 25 | $39.7M | $227.5M | ||
| Q2 25 | $52.7M | $102.0M | ||
| Q1 25 | $31.0M | $64.8M | ||
| Q4 24 | $52.8M | $242.5M | ||
| Q3 24 | $58.9M | $158.0M | ||
| Q2 24 | $-4.2M | $64.6M | ||
| Q1 24 | $15.9M | $130.3M |
| Q4 25 | $75.4M | $386.0M | ||
| Q3 25 | $38.0M | $214.3M | ||
| Q2 25 | $50.8M | $89.5M | ||
| Q1 25 | $24.8M | $54.1M | ||
| Q4 24 | $52.0M | $235.2M | ||
| Q3 24 | $57.8M | $149.9M | ||
| Q2 24 | $-5.3M | $53.0M | ||
| Q1 24 | $14.6M | $119.1M |
| Q4 25 | 70.4% | 47.9% | ||
| Q3 25 | 38.8% | 27.0% | ||
| Q2 25 | 52.9% | 13.0% | ||
| Q1 25 | 28.1% | 9.4% | ||
| Q4 24 | 57.1% | 37.5% | ||
| Q3 24 | 69.0% | 24.1% | ||
| Q2 24 | -7.5% | 9.0% | ||
| Q1 24 | 32.3% | 23.1% |
| Q4 25 | 2.0% | 0.3% | ||
| Q3 25 | 1.7% | 1.7% | ||
| Q2 25 | 2.0% | 1.8% | ||
| Q1 25 | 7.0% | 1.9% | ||
| Q4 24 | 0.9% | 1.2% | ||
| Q3 24 | 1.2% | 1.3% | ||
| Q2 24 | 1.6% | 2.0% | ||
| Q1 24 | 2.8% | 2.2% |
| Q4 25 | 1.51× | 2.53× | ||
| Q3 25 | 0.50× | 1.09× | ||
| Q2 25 | 1.38× | 0.95× | ||
| Q1 25 | 0.87× | 8.20× | ||
| Q4 24 | 1.16× | 2.35× | ||
| Q3 24 | 2.17× | 1.22× | ||
| Q2 24 | -0.27× | 0.99× | ||
| Q1 24 | 17.05× | 3.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KRYS
暂无分部数据
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
